NCT00975767

A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung Cancer

A Phase I/II Study of MGCD265 in Combination With Erlotinib or Docetaxel in Subjects With Advanced Malignancies and in Subjects With Advanced Non-Small Cell Lung Cancer (NSCLC)

• Status: Terminated
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 126 (actual)
• Sponsor: Mirati Therapeutics Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The main purpose of this study is to assess the safety profile of MGCD265 when administered in combination with the marketed anticancer drugs erlotinib and docetaxel.

Conditions

• Advanced Malignancies, Non-small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	MGCD265+erlotinib	MGCD265 and erlotinib administered daily
DRUG	MGCD265+docetaxel	MGCD265 administered daily; docetaxel administered once every 3 weeks

Timeline

• Start date: 2009-08-01
• Primary completion: 2013-07-01
• Completion: 2014-08-01
• First posted: 2009-09-11
• Last updated: 2015-01-08

Locations

5 sites across 1 country: United States